Even before the pandemic hit, the hair restoration industry was booming (it’s projected to reach over $12 billion in 2026). Add in the stress-included hair loss that we’ve seen during the COVID-19 pandemic, and suddenly all eyes are on the scalp.
It may be surprising that, in a market set to see significant growth in the next few years, we’re arguably lacking in great solutions to the problem — particularly for women, who aren’t always candidates for all the treatments currently available to men. In fact, of the two FDA-approved drugs on the hair rejuvenation market, minoxidil and finasteride (aka Rogaine and Propecia, respectively), only Rogaine is also approved for women. But with advances in technology and other innovations on the horizon, that all may change in the next few years.